REX American Resources Azioni (NYSE: REX)

REX American Resources (NYSE:REX) Azioni

REX American Resources

REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.

REX American Resources Corp

REX INTL HOLDINGS LTD ORD by Rex International Holdings Ltd

Rex International Holding Ltd

RIDEON EXPRESS HLDGS by Rideon Express Holdings

RIDE ON EXPRESS Holdings Co Ltd

Rexford Industrial Realty, Inc. Common Stock

Rexford Industrial Realty Inc

Rexford Industrial Realty, Inc. 5.875% Series B Cumulative Redeemable Preferred Stock

Rexford Industrial Realty, Inc. 5.625% Series C Cumulative Redeemable Preferred Stock, par value $0.01 per share

Truist Securities analyst Jordan Levy reiterates REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) with a Buy and lowers the price target from $55 to $50.

News

Price Target

Reiteration

Analyst Ratings

Truist Securities Reiterates Buy on REX American Resources, Lowers Price Target to $50

REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.28 by 125 percent. This is a 45.69 percent decrease over earnings of $1.16 per share from the same period last year. The company reported quarterly sales of $158.20 million which beat the analyst consensus estimate of $151.54 million by 4.39 percent. This is a 15.68 percent decrease over sales of $187.61 million the same period last year.

Earnings

Earnings Beats

REX American Resources Q4 2024 GAAP EPS $0.63 Beats $0.28 Estimate, Sales $158.20M Beat $151.54M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) is estimated to report quarterly loss at $5.00 per share on revenue of $5.60 million. 
• Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) is projected to report quarterly earnings at $2.18 per share on revenue of $8.23 billion. 
• Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $3.20 billion. 
• Titan America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTAM#NYSE">TTAM</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $384.72 million. 
• Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) is likely to report quarterly earnings at $1.06 per share on revenue of $2.60 billion. 
• SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) is expected to report quarterly loss at $0.03 per share on revenue of $202.71 million. 
• REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $152.00 million. 
• CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $358 thousand. 
• Target Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $80.10 million. 
• JinkoSolar Holding Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>) is estimated to report quarterly loss at $0.46 per share on revenue of $3.59 billion. 
• BRP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) is expected to report quarterly earnings at $0.62 per share on revenue of $1.35 billion. 
• Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) is expected to report quarterly loss at $0.14 per share on revenue of $88.50 million. 
• Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) is expected to report quarterly loss at $2.94 per share on revenue of $4.28 million. 
• Cheetah Mobile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMCM#NYSE">CMCM</a>) is expected to report earnings for its fourth quarter. 
• Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) is projected to report quarterly earnings at $1.48 per share on revenue of $1.51 billion. 
• Zhihu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZH#NYSE">ZH</a>) is projected to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• Snail (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAL#NASDAQ">SNAL</a>) is estimated to report earnings for its fourth quarter. 
• Integra Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITRG#AMEX">ITRG</a>) is likely to report earnings for its fourth quarter. 
• TAT Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TATT#NASDAQ">TATT</a>) is likely to report earnings for its fourth quarter. 
• Envela (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELA#AMEX">ELA</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $40.63 million. 
• 3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) is projected to report quarterly loss at $0.11 per share on revenue of $114.96 million. 
• BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) is projected to report quarterly loss at $0.87 per share on revenue of $20 thousand. 
• Oxbridge Re Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXBR#NASDAQ">OXBR</a>) is projected to report earnings for its fourth quarter. 
• Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $6.91 million. 
• Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $14.21 million. 
• Zepp Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZEPP#NYSE">ZEPP</a>) is expected to report earnings for its fourth quarter. 
• FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) is projected to report quarterly loss at $0.03 per share on revenue of $33.09 million. 
• Jefferies Financial Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEF#NYSE">JEF</a>) is projected to report quarterly earnings at $1.13 per share on revenue of $1.97 billion. 
• Microvision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $2.10 million. 
• H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) is projected to report quarterly earnings at $0.63 per share on revenue of $797.68 million. 
• Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) is expected to report quarterly loss at $0.06 per share on revenue of $1.35 million. 
• Usio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USIO#NASDAQ">USIO</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $21.40 million. 
• Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) is estimated to report quarterly earnings at $1.27 per share on revenue of $276.82 million. 
• Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) is estimated to report quarterly earnings at $3.01 per share on revenue of $2.47 billion. 
• Spruce Power Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) is projected to report earnings for its fourth quarter. 
• Steelcase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $790.90 million. 
• Guardian Pharmacy Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $320.52 million. 
• Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) is expected to report quarterly loss at $0.26 per share on revenue of $232 thousand. 
• MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) is projected to report quarterly earnings at $0.44 per share on revenue of $918.88 million. 
• Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $87.50 million. 
• Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) is estimated to report earnings for its Fiscal Year 2024. 
• Petco Health and Wellness (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $1.56 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALUR

ALVO

BCDA

CATX

CHWY

CLGN

CMCM

CNXC

CTAS

DERM

DLTR

DOOO

DRRX

DTIL

DYAI

GRDN

ITRG

MLKN

MVIS

OXBR

PAYX

SAIL

SNAL

Spruce Power Holding Corporation Class A Common Stock

SPRU

TATT

TTAM

USIO

VRNT

WOOF

ZEPP

Earnings Scheduled For March 26, 2025

Truist Securities analyst Jordan Levy maintains REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) with a Buy and lowers the price target from $60 to $55.

Truist Securities Maintains Buy on REX American Resources, Lowers Price Target to $55

The earnings results for REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) for Q3 were made public on Tuesday, December 3, 2024 at 07:30 AM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
REX American Resources beat estimated earnings by 92.0%, reporting an EPS of $1.38 versus an estimate of $0.72.
Revenue was down $46.20 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
Last quarter the company beat on EPS by $0.26 which was followed by a 1.0% drop in the share price the next day.
Here's a look at REX American Resources's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.44</td>
<td>0.40</td>
<td>0.68</td>
<td>0.68</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.70</td>
<td>0.58</td>
<td>1.16</td>
<td>1.49</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>146.00M</td>
<td>165.28M</td>
<td>190.26M</td>
<td>205.99M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>148.16M</td>
<td>161.23M</td>
<td>187.61M</td>
<td>221.08M</td>
</tr>
</tbody>
</table>

To track all earnings releases for REX American Resources <a href="https://www.benzinga.com/quote/REX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

REX American Resources Earnings Review: Q3 Summary

WIIM

REX American Resources shares are trading higher after the company reported better-than-expected Q3 financial results.

Commodities

Markets

General

REX American Resources Reported Q3 Consolidated Ethanol Sales Volumes Of 75.5M Gallons, An Increase Of Approximately 3% Compared To The Same Period In Fiscal 2023

REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) reported quarterly earnings of $1.38 per share which beat the analyst consensus estimate of $0.63 by 119.05 percent. The company reported quarterly sales of $174.88 million which beat the analyst consensus estimate of $158.51 million by 10.33 percent. This is a 20.90 percent decrease over sales of $221.08 million the same period last year.

REX American Resources Q3 2024 GAAP EPS $1.38 Beats $0.63 Estimate, Sales $174.88M Beat $158.51M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Core &amp; Main (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNM#NYSE">CNM</a>) is likely to report quarterly earnings at $0.66 per share on revenue of $1.99 billion. 
• Citi Trends (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRN#NASDAQ">CTRN</a>) is expected to report quarterly loss at $0.75 per share on revenue of $178.48 million. 
• REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) is estimated to report quarterly earnings at $0.72 per share on revenue of $159.00 million. 
• Bank of Nova Scotia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNS#NYSE">BNS</a>) is likely to report quarterly earnings at $1.16 per share on revenue of $6.16 billion. 
• Donaldson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCI#NYSE">DCI</a>) is estimated to report quarterly earnings at $0.82 per share on revenue of $892.43 million. 
<h3>Companies Reporting After The Bell</h3>
• Descartes Systems Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGX#NASDAQ">DSGX</a>) is projected to report quarterly earnings at $0.42 per share on revenue of $164.12 million. 
• Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $116.94 million. 
• Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $284.29 million. 
• Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) is projected to report quarterly earnings at $0.42 per share on revenue of $818.14 million. 
• Box (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) is likely to report quarterly earnings at $0.42 per share on revenue of $275.10 million. 
• Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) is expected to report quarterly earnings at $0.58 per share on revenue of $649.64 million. 
• Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $1.46 billion. 
• Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) is projected to report quarterly loss at $0.08 per share on revenue of $50.77 million. 
• Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) is estimated to report quarterly earnings at $2.44 per share on revenue of $9.34 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BASE

CTRN

CURV

DSGX

MRVL

NOTV

OKTA

PSTG

Earnings Scheduled For December 3, 2024

REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) will release its quarterly earnings report on Tuesday, 2024-12-03. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate REX American Resources to report an earnings per share (EPS) of $0.72.
Investors in REX American Resources are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.26, leading to a 0.6% drop in the share price on the subsequent day.
Here's a look at REX American Resources's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.44</td>
<td>0.40</td>
<td>0.68</td>
<td>0.68</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.70</td>
<td>0.58</td>
<td>1.16</td>
<td>1.49</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-4.0%</td>
<td>34.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1733148100_0.png" alt="eps graph" />
<h3>Performance of REX American Resources Shares</h3>
Shares of REX American Resources were trading at $43.31 as of November 28. Over the last 52-week period, shares are up 0.81%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/REX/earnings">To track all earnings releases for REX American Resources visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look at REX American Resources's Upcoming Earnings Report

Truist Securities analyst Jordan Levy reiterates REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) with a Buy and maintains $60 price target.

Truist Securities Reiterates Buy on REX American Resources, Maintains $60 Price Target

REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.54 by 29.63 percent. This is a 34.62 percent increase over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $148.16 million which beat the analyst consensus estimate of $146.00 million by 1.48 percent. This is a 30.11 percent decrease over sales of $211.98 million the same period last year.

REX American Resources Q2 2024 GAAP EPS $0.70 Beats $0.54 Estimate, Sales $148.16M Beat $146.00M Estimate

Truist Securities analyst Jordan Levy maintains REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) with a Buy and lowers the price target from $65 to $60.

Truist Securities Maintains Buy on REX American Resources, Lowers Price Target to $60

Ratings for REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for REX American Resources, presenting an average target of $64.5, a high estimate of $70.00, and a low estimate of $58.00. This upward trend is evident, with the current average reflecting a 2.79% increase from the previous average price target of $62.75.
<img src="https://www.benzinga.com/files/images/story/2024/1718647280_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive REX American Resources. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to REX American Resources. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of REX American Resources compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for REX American Resources's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of REX American Resources's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/REX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on REX American Resources analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind REX American Resources</h2>
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
<h3>REX American Resources's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining REX American Resources's financials over 3 months reveals challenges. As of 30 April, 2024, the company experienced a decline of approximately -24.2% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.
Net Margin: REX American Resources's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.32%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): REX American Resources's ROE excels beyond industry benchmarks, reaching 1.96%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): REX American Resources's ROA excels beyond industry benchmarks, reaching 1.53%. This signifies efficient management of assets and strong financial health.
Debt Management: REX American Resources's debt-to-equity ratio is below the industry average at 0.02, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 4 Ratings For REX American Resources

Truist Securities analyst Jordan Levy maintains REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) with a Buy and maintains $65 price target.

Truist Securities Maintains Buy on REX American Resources, Maintains $65 Price Target

Truist Securities analyst Jordan Levy reiterates REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) with a Buy and lowers the price target from $70 to $65.

Truist Securities Reiterates Buy on REX American Resources, Lowers Price Target to $65

REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) reported quarterly earnings of $0.58 per share which beat the analyst consensus estimate of $0.40 by 45 percent. This is a 93.33 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $161.23 million which missed the analyst consensus estimate of $165.28 million by 2.45 percent. This is a 24.20 percent decrease over sales of $212.71 million the same period last year.

Earnings Misses

REX American Resources Q1 EPS $0.58 Beats $0.40 Estimate, Sales $161.23M Miss $165.28M Estimate

Truist Securities analyst Jordan Levy reiterates REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) with a Buy and raises the price target from $58 to $70.

Truist Securities Reiterates Buy on REX American Resources, Raises Price Target to $70

Truist Securities analyst Jordan Levy maintains REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) with a Buy and maintains $58 price target.

Truist Securities Maintains Buy on REX American Resources, Maintains $58 Price Target

Shares of Kodiak Sciences Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kod#NASDAQ">KOD</a>) fell sharply during Thursday&rsquo;s session after the company reported a wider-than-expected fourth-quarter loss.
Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share.
Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Avalo Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avtx#NASDAQ">AVTX</a>) shares jumped 430% to $25.35 after the company announced it acquired a Phase 2-ready anti-IL-1&beta; mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing of up to $185 million.</li>
<li>Xilio Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xlo#NASDAQ">XLO</a>) gained 146% to $1.58 after the company announced an exclusive license agreement with Gilead Sciences for a tumor-activated IL-12 program. The company announced a $11.3 million private placement equity financing.</li>
<li>Biodexa Pharmaceuticals Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bdrx#NASDAQ">BDRX</a>) shares climbed 80% to $1.5395. Biodexa&#39;s MTX110 showed promise in extending life expectancy against aggressive brain cancers.</li>
<li>Ontrak, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otrk#NASDAQ">OTRK</a>) gained 55% to $0.9239.</li>
<li>Binah Capital Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcg#NASDAQ">BCG</a>) gained 48% to $14.05 after dipping more than 20% on Wednesday.</li>
<li>Kidpik Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pik#NASDAQ">PIK</a>) gained 40.7% to $4.5999. Kidpik recently regained compliance with the Nasdaq minimum bid price requirement.</li>
<li>Allego N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/allg#NASDAQ">ALLG</a>) rose 32.8% to $1.7650.</li>
<li>Akanda Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akan#NASDAQ">AKAN</a>) gained 28% to $0.2053 after the company announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry.</li>
<li>Destiny Tech100 Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NASDAQ">DXYZ</a>) rose 26% to $22.15.</li>
<li>REX American Resources Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rex#NYSE">REX</a>) gained 23.2% to $54.15 following upbeat earnings.</li>
<li>Nutriband Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntrb#NASDAQ">NTRB</a>) gained 23% to $4.98. Nutriband recently provided a clinical and regulatory path overview for its AVERSA Fentanyl patch.</li>
<li>Summit Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smmt#NASDAQ">SMMT</a>) gained 22.8% to $4.6050.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cero#NASDAQ">CERO</a>) gained 22.7% to $2.00.</li>
<li>Hut 8 Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hut#NASDAQ">HUT</a>) gained 20.4% to $11.87. Hut 8 Corp reported revenue of C$60.6 million for the six months ended Dec. 31, 2023.</li>
<li>Matterport, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mttr#NASDAQ">MTTR</a>) rose 16.8% to $2.2802.</li>
<li>RH (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rh#NYSE">RH</a>) rose 16.2% to $344.99 following the release of quarterly results. RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast.</li>
<li>Cazoo Group Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/czoo#NASDAQ">CZOO</a>) gained 15.5% to $14.52 after jumping over 100% on Wednesday.</li>
<li>Sutro Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stro#NASDAQ">STRO</a>) surged 14.4% to $5.64. Oppenheimer analyst Jay Olson maintained Sutro Biopharma with an Outperform and maintained a $10 price target.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktra#NASDAQ">KTRA</a>) shares rose 14.1% to $0.1021. Kintara Therapeutics announced expansion of REM-001 clinical study to include patients on pembrolizumab.</li>
<li>Nikola Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nkla#NASDAQ">NKLA</a>) gained 12.7% to $1.0250.</li>
<li>OPKO Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opk#NASDAQ">OPK</a>) climbed 12.1% to $1.1996. Labcorp announced acquisition of select assets of BioReference Health&#39;s Diagnostics Business.</li>
<li>Altimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alt#NASDAQ">ALT</a>) climbed 11.4% to $9.90. Altimmune recently released lean mass preservation data for pemvidutide and worse-than-expected fourth-quarter FY23 earnings.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mara#NASDAQ">MARA</a>) gained 10.4% to $24.37.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dna#NYSE">DNA</a>) rose 7.1% to $1.1786. Ginkgo Bioworks announced that it has been awarded a contract for up to $6 million from the Defense Advanced Research Projects Agency.</li>
<li>The Est&eacute;e Lauder Companies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/el#NYSE">EL</a>) gained 5.4% to $152.85 after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $160 to $170.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Primech Holdings Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pmec#NASDAQ">PMEC</a>) shares fell 46.7% to $2.07 after the company issued financial updates and corporate highlights for the six months ended Sept. 30, 2023.</li>
<li>Gamida Cell Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gmda#NASDAQ">GMDA</a>) fell 28.1% to $0.0427. Gamida Cell shares dipped over 82% on Wednesday after the company reported fourth-quarter results and disclosed the commencement of a restructuring process.</li>
<li>Data Storage Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dtst#NASDAQ">DTST</a>) dipped 24% to $5.81 following fourth-quarter results.</li>
<li>urban-gro, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ugro#NASDAQ">UGRO</a>) declined 22.9% to $1.3992 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Presto Automation Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prst#NASDAQ">PRST</a>) fell 22% to $0.1493. Presto Automation recently entered securities purchase agreements relating to the issuance and sale of 4.8 million shares</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tnxp#NASDAQ">TNXP</a>) dipped 19.6% to $0.2629. Tonix Pharmaceuticals announced pricing of $4.4 million registered direct offering.</li>
<li>MillerKnoll, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mlkn#NASDAQ">MLKN</a>) shares fell 17.2% to $25.28 as the company reported downbeat sales for its third quarter and issued weak guidance for the fourth quarter.</li>
<li>Sezzle Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sezl#NASDAQ">SEZL</a>) fell 16.6% to $77.13.</li>
<li>NuCana plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncna#NASDAQ">NCNA</a>) fell 16.3% to $0.2616. NuCana announced a plan to implement 1-for-25 ADS ratio change.</li>
<li>SOBR Safe, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sobr#NASDAQ">SOBR</a>) fell 13.7% to $0.4460 after gaining 12% on Wednesday.</li>
<li>Murano Global Investments Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrno#NASDAQ">MRNO</a>) fell 13% to $12.97.</li>
<li>22nd Century Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xxii#NASDAQ">XXII</a>) fell 12.5% to $ 0.1151 as the company posted fourth-quarter results and announced stock split of 1-for-16.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) declined 10.9% to $1,710.01.</li>
<li>Hitek Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hkit#NASDAQ">HKIT</a>) fell 10.3% to $1.56 after gaining over 22% on Wednesday.</li>
<li>Movella Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mvla#NASDAQ">MVLA</a>) fell 10.2% to $0.0678 after dipping 20% on Wednesday.</li>
<li>Abits Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abts#NASDAQ">ABTS</a>) fell 10.2% to $0.70.</li>
<li>Reddit, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rddt#NYSE">RDDT</a>) fell 9.4% to $52.32.</li>
<li>Braze, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brze#NASDAQ">BRZE</a>) dipped 9.3% to $45.90 after the company issued soft EPS guidance for FY25.</li>
<li>The Chemours Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cc#NYSE">CC</a>) shares dropped 6.2% to $27.09 after the company reported fourth-quarter results. The company also said it identified four material weaknesses amid its internal control over financial reporting.</li>
<li>GCT Semiconductor Holding Inc, (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gcts#NYSE">GCTS</a>) fell 5.1% to $41.77 amid volatility following the company&#39;s recently completed business combination with Concord Acquisition Corp III and NYSE debut.</li>
<li>Carnival Corporation &amp; plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ccl#NYSE">CCL</a>) fell 4% to $16.52. Carnival posted a narrower-than-expected loss for its first quarter on Wednesday.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37975916/jim-cramer-likes-crown-castle-but-cant-recommend-archer-aviation-it-has-no-earnings-powe"> Jim Cramer Likes Crown Castle, But Can&#39;t Recommend Archer Aviation: It Has &#39;No Earnings Power&#39; </a>

Penny Stocks

Small Cap

Intraday Update

Movers

Trading Ideas

ABTS

AKAN

ALLG

AVTX

BDRX

BRZE

CERO

CZOO

DTST

DXYZ

GCTS

GMDA

HKIT

Kintara Therapeutics, Inc. - Common Stock

KTRA

MARA

MRNO

MSTR

MTTR

MVLA

NCNA

NKLA

NTRB

OTRK

PMEC

PRST

RDDT

SEZL

SMMT

SOBR

STRO

TNXP

UGRO

XXII

Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Press Releases

REX American Resources to Report Q1 2024 Results and Host a Conference Call and Webcast on May 22, 2024

REX American Resources Reports Fiscal 2024 First Quarter Net Income Per Share Attributable to REX Common Shareholders of $0.58

REX American Resources to Report Fiscal Q2 2024 Results and Host a Conference Call and Webcast on August 27, 2024

REX American Resources Corporation to Participate in Upcoming Investor Events

REX American Resources Reports Fiscal 2024 Second Quarter Net Income Per Share Attributable to REX Common Shareholders of $0.70 vs. $0.52 Per Share in Fiscal Second Quarter 2023

REX American Resources to Report Fiscal Q3 2024 Results and Host a Conference Call and Webcast on December 3, 2024

REX American Resources Reports Fiscal 2024 Third Quarter Net Income Per Share Attributable to REX Common Shareholders of $1.38, the Second-Best Quarterly Result in Company History

REX American Resources to Report Q4 and Full Fiscal Year 2024 Results and Host a Conference Call and Webcast on March 26, 2025

REX American Resources Reports Full Fiscal Year 2024 Net Income Per Share Attributable to REX Common Shareholders of $3.30

Comments

REX American Resources

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO